A retrospective study analyzing interleukin (IL)-1 inhibitors in monogenic autoinflammatory disorders (mAID) treated with anakinra or canakinumab.
Latest Information Update: 18 May 2021
At a glance
- Drugs Anakinra (Primary) ; Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes; Familial Mediterranean fever; Hereditary autoinflammatory diseases; Mevalonate Kinase Deficiency
- Focus Therapeutic Use
- 18 May 2021 New trial record
- 07 May 2021 Primary endpoint (Overall drug retention rate (DRR)) has been met, according to the results published in the Rheumatology.
- 07 May 2021 Results published in the Rheumatology